# US 2020/0392235 A1 · Novel il-15 prodrugs and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392235 A1
- Document ID: US20200392235A1
- Status: Published application
- Kind: A1
- Application number: 16/900,677
- Filed: 2020-06-12
- Published: 2020-12-17
- Earliest claimed: 2019-06-12
- Assignees: AskGene Pharma Inc.
- Applicants: Askgene Pharma, Inc.
- Inventors: Yuefeng LU; Chunxiao YU; Jian-Feng LU
- Web page: https://patentgrep.com/patent/US20200392235A1

## CPC

- C07K 14/5443: {IL-15}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 14/7155: {for interleukins [IL]}
- C07K 14/811: {Serine protease (E.C. 3.4.21) inhibitors}
- C07K 14/8146: {Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP}
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/70: containing domain for protein-protein interaction
- C12Y 304/21109: Matriptase (3.4.21.109)
- C12Y 304/24024: Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
- C12Y 304/24035: Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

## Claims

### Claim 1

A prodrug comprising an IL-15 cytokine moiety (A), a masking moiety (M), a carrier moiety (C), and a Sushi domain (S), wherein
the masking moiety binds to the IL-15 cytokine moiety and inhibits a biological activity of the IL-15 cytokine moiety,
the masking moiety is fused to the carrier moiety,
the Sushi domain is fused to the carrier moiety, and
the IL-15 cytokine moiety is fused to the Sushi domain.

### Claim 2 (depends on 1)

The prodrug of claim 1, wherein
the masking moiety is fused to the carrier moiety through a first peptide linker,
the Sushi domain is fused to the carrier moiety through a second peptide linker, and
the IL-15 cytokine moiety is fused to the Sushi domain through a third peptide linker, and
wherein at least one of the three peptide linkers is cleavable.

### Claim 3 (depends on 2)

The prodrug of claim 2, wherein the third peptide linker is at least 15, 20, 25, or 30 amino acids in length, optionally wherein the third peptide linker comprises SEQ ID NO: 139 or 140.

### Claim 4

A prodrug comprising an IL-15 cytokine moiety (A), a masking moiety (M), a carrier moiety (C), and a Sushi domain (S), wherein
the masking moiety binds to the IL-15 cytokine moiety and inhibits a biological activity of the IL-15 cytokine moiety,
the IL-15 cytokine moiety is fused to the carrier moiety,
the Sushi domain is fused to the carrier moiety, and
the masking moiety is fused to the Sushi domain.

### Claim 5 (depends on 4)

The prodrug of claim 4, wherein
the IL-15 cytokine moiety is fused to the carrier moiety through a first peptide linker,
the Sushi domain is fused to the carrier moiety through a second peptide linker, and
the masking moiety is fused to the Sushi domain through a third peptide linker, and optionally wherein at least one of the three peptide linkers is cleavable.

### Claim 6 (depends on 1)

The prodrug of claim 1, wherein the masking moiety comprises an extracellular domain (ECD) of a receptor of the IL-15 cytokine moiety.

### Claim 7 (depends on 6)

The prodrug of claim 6, wherein the masking moiety comprises an ECD of human IL-2Rβ or a functional analog thereof, and/or an ECD of human IL-2Rγ or a functional analog thereof.

### Claim 8 (depends on 7)

The prodrug of claim 7, wherein the ECD of human IL-2Rγ or a functional analog thereof comprises SEQ ID NO: 6, or an amino acid sequence at least 90% identical thereto, and/or wherein the ECD of human IL-2Rβ or a functional analog thereof comprises SEQ ID NO: 3, 4, or 5, or an amino acid sequence at least 90% thereto.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The prodrug of claim 1, wherein the masking moiety comprises an antibody fragment that binds to the IL-15 cytokine moiety.

### Claim 11

A prodrug comprising an IL-15 cytokine moiety (A), a masking moiety (M), a carrier moiety (C), and optionally a Sushi domain (S), wherein
the masking moiety comprises an antibody fragment that binds to the IL-15 cytokine moiety and inhibits a biological activity of the IL-15 cytokine moiety, and
the masking moiety is fused to the carrier moiety, to the IL-15 cytokine moiety, or to the Sushi domain through a peptide linker.

### Claim 12 (depends on 10)

The prodrug of claim 10, wherein the antibody fragment is an ScFv or Fab comprising heavy chain CDR1-3 and light chain CDR1-3 of an anti-IL-15 antibody selected from 146B7, 146H5, 404E4, and 404A8.

### Claim 13 (depends on 10)

The prodrug of claim 10, wherein
the antibody fragment comprises heavy chain CDR (HCDR) 1 comprising SEQ ID NO: 100, HCDR2 comprising SEQ ID NO: 101, HCDR3 comprising SEQ ID NO: 102 or 106, light chain CDR (LCDR) 1 comprising SEQ ID NO: 103, LCDR2 comprising SEQ ID NO: 104, and LCDR3 comprising SEQ ID NO: 105; or
the antibody fragment comprises (i) a heavy chain variable domain comprising SEQ ID NO: 107 or an amino acid sequence at least 95% identical thereto, and a light chain variable domain comprising SEQ ID NO: 108 or 123 or an amino acid sequence at least 95% identical thereto; (ii) SEQ ID NO: 109; (iii) SEQ ID NO: 110; or (iv) SEQ ID NO: 124.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The prodrug of claim 13, wherein the Cys residue of the heavy chain CDR3 is mutated to Ser, Thr, Met, Ala, Gly, Asn or Gln.

### Claim 16 (depends on 1)

The prodrug of claim 1, wherein the masking moiety does not interfere with or has minimum impact on the binding of the IL-15 cytokine moiety to IL-15Rα.

### Claim 17 (depends on 1)

The prodrug of claim 1, wherein the IL-15 cytokine moiety is a human IL-15 polypeptide comprising SEQ ID NO: 2 or a mutein thereof.

### Claim 18 (depends on 17)

The prodrug of claim 17, wherein the human IL-15 polypeptide comprises one or more mutations selected from N1A, N1D, N4A, N4D, I6T, S7A, D8A, D8T, D8E, D8N, K10A, K10D, K11A, K11D, E46, V49, L45, S51, L52, D61A, D61N, T62L, T62A, E64A, E64L, E64K, E64Q, N65A, N65L, N65D, L66D, L66E, I67D, I67E, I68S, 168E, L69S, L69E, N72A, N72D, V63E, V63D, L66E, L66D, I67E, I67D, Q108E, N112A, N1D/D61N, N1D/E64Q, N4D/D61N, N4D/E64Q, D8N/D61N, D8N/E64Q, D61N/E64Q, E64Q/Q108E, N1D/N4D/D8N, D61N/E64Q/N65D, N1D/D61N/E64Q, N1D/Q108E, N1D/D61N/E64Q/Q108E, N4D/D61N/E64Q/Q108E, and D30N/E64Q/N65D relative to SEQ ID NO: 2.

### Claim 19 (depends on 1)

The prodrug of claim 1, wherein the carrier moiety is a PEG molecule, an albumin, an albumin fragment, an antibody Fc domain, or an antibody or an antigen-binding fragment thereof.

### Claim 20 (depends on 19)

The prodrug of claim 19, wherein the carrier moiety is an antibody Fc domain or an antibody comprising mutations L234A and L235A (“LALA”) (EU numbering).

### Claim 21 (depends on 19)

The prodrug of claim 19, wherein the carrier moiety is an antibody Fc domain or an antibody comprising knobs-into-holes mutations, and wherein the IL-15 cytokine moiety and the masking moiety are fused to different polypeptide chains of the antibody Fc domain or to the different heavy chains of the antibody.

### Claim 22 (depends on 21)

The prodrug of claim 21, wherein
the knobs-into-holes mutations comprise a T366Y “knob” mutation on a polypeptide chain of the Fc domain or a heavy chain of the antibody, and a Y407T “hole” mutation in the other polypeptide of the Fc domain or the other heavy chain of the antibody, or
the knobs-into-holes mutations comprise Y349C and/or T366W mutations in the CH3 domain of the “knob chain” and E356C, T366S, L368A, and/or Y407V mutations in the CH3 domain of the “hole chain” (EU numbering).

### Claim 23 (depends on 19)

The prodrug of claim 19, wherein the carrier moiety is an IgG4 Fc domain, and wherein said first polypeptide comprises an amino acid sequence at least 99% identical as one shown in SEQ ID NOs: 80, 81 or 87, and said second polypeptide chain comprises an amino acid sequence at least 99% identical as one selected from SEQ ID NOs: 82-86.

### Claim 24 (depends on 19)

The prodrug of claim 19, wherein
the carrier moiety is an anti-PD-1 antibody comprising a light chain having an amino acid sequence at least 99% identical to SEQ ID NO: 55 or 56; a first heavy chain having an amino acid sequence at least 99% identical to SEQ ID NO: 54, 60, or 61; and a second heavy chain having an amino acid sequence at least 99% identical to SEQ ID NO: 52, 53, 58, 59, 62, 63, or 69, or
the carrier moiety is an anti-PD-1 antibody comprising a light chain having an amino acid sequence at least 99% identical to SEQ ID NO: 55; a first heavy chain having an amino acid sequence at least 99% identical to SEQ ID NO: 66; and a second heavy chain having an amino acid sequence at least 99% identical to SEQ ID NO: 64, 65, 67, or 68; or
the carrier moiety is an anti-PD-L1 antibody comprising a light chain having an amino acid sequence at least 99% identical to SEQ ID NO: 50 or 51; a first heavy chain having an amino acid at least 99% identical to SEQ ID NO: 47, 48 or 49; and a second heavy chain having an amino acid sequence at least 99% identical to SEQ ID NO: 45 or 46.

### Claim at position 25

25-26. (canceled)

### Claim 27 (depends on 19)

The prodrug of claim 19, wherein the carrier moiety is an antibody or an antigen-binding fragment thereof that specifically binds to one or more antigens selected from PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, CD47, and TIGIT.

### Claim 28 (depends on 19)

The prodrug of claim 19, wherein the carrier moiety is an antibody Fc domain or an antibody, and the prodrug comprises the following polypeptide pairs (from N-terminus to C-terminus):
a. C1-A and C2-S-M,
b. A-C1 and M-S-C2,
c. C1-S-A and C2-M,
d. C1-A-S and C2-M,
e. S-A-C1 and M-C2, or
f. A-S-C1 and M-C2; and
wherein C1 and C2 are the first and second polypeptide chains, respectively, of the Fc domain, or are the first and second heavy chains, respectively, of the antibody; and “—” is a direct peptidyl bond or a peptide linker.

### Claim 29 (depends on 1)

The prodrug of claim 1, wherein the Sushi domain comprises SEQ ID NO: 7 or 9, or an amino acid sequence at least 90% identical thereto.

### Claim 30 (depends on 1)

The prodrug of claim 1, wherein at least one of the first, second, and third peptide linkers is a noncleavable peptide linker, optionally selected from SEQ ID NOs: 11-16.

### Claim 31 (depends on 1)

The prodrug of claim 1, wherein at least one of the first, second, and third peptide linkers is a cleavable peptide linker comprising a substrate sequence of urokinase-type plasminogen activator (uPA) matriptase; matrix metallopeptidase (MMP) 2; MMP9; both uPA and MMP2; both uPA and MMP9; all of uPA, MMP2 and MMP9; or both MMP2 and matriptase.

### Claim 32

(canceled)

### Claim 33 (depends on 31)

The prodrug of claim 31, wherein the cleavable peptide linker comprises an amino acid sequence selected from SEQ ID NOs: 17-36.

### Claim 34 (depends on 31)

The prodrug of claim 31, wherein the cleavable peptide linker is cleavable by one or more proteases located at a tumor site or its surrounding environment, and the cleavage leads to activation of the prodrug at the tumor site or surrounding environment.

### Claim 35 (depends on 1)

A pharmaceutical composition comprising the prodrug of claim 1 and a pharmaceutically acceptable excipient.

### Claim 36 (depends on 1)

A polynucleotide or polynucleotides encoding the prodrug of claim 1.

### Claim 37 (depends on 36)

An expression vector or vectors comprising the polynucleotide or polynucleotides of claim 36.

### Claim 38 (depends on 37)

A host cell comprising the vector(s) of claim 37.

### Claim 39

(canceled)

### Claim 40 (depends on 38)

A method of making a cytokine prodrug, comprising
culturing the host cell of claim 38 under conditions that allow expression of the prodrug, wherein the host cell is a mammalian cell, and
isolating the prodrug.

### Claim 41 (depends on 35)

A method of treating a cancer or an infectious disease or stimulating the immune system in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 35.

### Claim 42

(canceled)
